Boston Scientific (BSX) stock was down 1.02% at $91.75, underperforming the S&P 500. Analysts project earnings of $0.78 per share, a 11.43% increase. Revenue is estimated at $5.27 billion, up 15.46%. BSX carries a Zacks Rank of #2 (Buy) and is trading at a Forward P/E ratio of 30.54, higher than the industry average.

The upcoming earnings release of Boston Scientific is highly anticipated, with expectations of $0.78 earnings per share and $5.27 billion in revenue. Analysts’ outlook on the company’s health and profitability is positive, reflected in recent estimate revisions. Boston Scientific is trading at a premium to its industry, with a Zacks Rank of #2 (Buy).

Boston Scientific is currently trading at a premium to its industry with a Forward P/E ratio of 30.54. Analysts anticipate earnings of $3.04 per share and revenue of $20.06 billion for the year, showing positive shifts from last year. The Zacks Rank system suggests a favorable outlook for BSX, with a history of outperforming since 1988.

Read more at Nasdaq: Boston Scientific (BSX) Stock Falls Amid Market Uptick: What Investors Need to Know